Background: During the past decade, a huge interest was devoted to the type-2 diabetes mellitus and their associations with prostate cancer development.Objectives: The aim of this study was to determine whether type 2 diabetes mellitus and treatment with metformin is associated with prostate cancer risk.Materials and methods: The cohort was composed of diabetic male patients identified in the National Health Insurance Fund database during 2000-2016 and cancer cases in national Cancer Registry. We calculated standardized incidence ratios (SIR) for prostate cancers as a ratio of observed number of cancer case in people with diagnosis of diabetes to the expected number of cancer cases in the underlying general population.Results: 2754 prostate cancers were observed versus 3111.26 expected within the period of observation entailing an SIR of 0.89 (95% CI: 0.85-0.92). Significantly lower risk of prostate cancer was found in diabetes patients in all age groups, also was in metformin-users and never-users' groups, with higher risk reduction in metformin-users (SIR 0.71, 95% CI: 0.68-0.75) than in diabetes patients never-users (SIR 0.88, 95% CI: 0.80-0.96).Conclusion: In this large population-based study, we found a significantly decreased risk of prostate cancer among men with diabetes and metformin-users.

中文翻译：

---

在立陶宛糖尿病患者队列中降低患前列腺癌的风险。

背景：在过去的十年中，人们对 2 型糖尿病及其与前列腺癌发展的关系产生了极大的兴趣。目的：本研究的目的是确定 2 型糖尿病和二甲双胍治疗是否与前列腺癌有关。癌症风险。材料和方法：该队列由 2000-2016 年国家健康保险基金数据库中确定的糖尿病男性患者和国家癌症登记处的癌症病例组成。我们将前列腺癌的标准化发病率 (SIR) 计算为在诊断为糖尿病的人群中观察到的癌症病例数与基础普通人群中预期的癌症病例数之比。结果：观察到 2754 例前列腺癌，而预期为 3111.26 例。 SIR 为 0 的观察期。89 (95% CI: 0.85-0.92)。在所有年龄组的糖尿病患者中发现前列腺癌的风险显着降低，二甲双胍使用者和从不使用者组也发现，二甲双胍使用者的风险降低更高（SIR 0.71，95% CI：0.68-0.75）在从未使用过的糖尿病患者中 (SIR 0.88, 95% CI: 0.80-0.96)。结论：在这项基于人群的大型研究中，我们发现糖尿病男性和二甲双胍使用者患前列腺癌的风险显着降低。